17
Views
31
CrossRef citations to date
0
Altmetric
Original Article

Malignancy in Association with Polymyalgia Rheumatica and Temporal Arteritis

&
Pages 129-135 | Received 20 Sep 1973, Published online: 12 Jul 2009
 

Abstract

In a series of 45 patients with polymyalgia rheumatica (PMR) and/or temporal arteritis (TA), the clinical course in four of six fatal cases was associated with malignancy. In one case the poiymyalgic symptoms were clearly associated with the recurrence of a previously operated uterine carcinoma. This case represented a paraneoplastic phenomenon and responded poorly to corticosteroid treatment. In another patient, who died of myocardial infarction one year after the onset of TA, a clinically silent brain tumour was found on autopsy. In the third patient a malignant lymphoma occurred 4 years after the diagnosis of PMR was made, and in the fourth case TA and PMR preceded the discovery of a metastasizing adenocarcinoma of unknown origin by 3 years. In the latter three cases the long interval between the onset of the poiymyalgic symptoms and the discovery of malignancy and the excellent response to steroid treatment were not consistent with a paraneoplastic mechanism of the rheumatic symptoms. The observed incidence of neoplasms during the follow-up period in this material did not differ significantly from the anticipated number of neoplasms in the same age groups of the normal population.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.